About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 1NCT04830358

Safety and Immunogenicity of the 'EuPCV15' in Healthy Korean Adults

The safety and immunogenicity of EuPCV15 compared to Prevenar13 are assessed in healthy adults.

Lead sponsor: EuBiologics Co.,Ltd•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

EuBiologics Co.,Ltd

Age

19 - 50 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. Healthy adults aged 19 to 50 years old
•2. Participants willing to give written informed consent to participate in the trial

Exclusion Criteria

•1. History of invasive pneumococcal infection within 5 years at screening
•2. Known hypersensitivity to any component of the study vaccine
•3. Immune deficiency or immunosuppressive disorder
•4. Immunized with any licensed vaccine within 4 weeks prior to screening
•5. Pregnant, lactating women or women of childbearing age not using a reliable method of contraception
•6. Participants who in the opinion of the investigator will not be able to comply with any of the protocol required procedure

Related studies

RECRUITINGPhase 1

Serum Collection Study for Assay Development

NCT07205289 · Pneumococcal Disease, Invasive, Pneumococcal Disease

RECRUITINGPhase 4

Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15

NCT06731374 · Pneumococcal Disease, Pneumococcal Carriage

RECRUITINGPhase 3

A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People

NCT06044077 · Pneumococcal Disease

Active Not RecruitingPhase 2

Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants

NCT06790290 · Pneumococcal Disease, Invasive

COMPLETEDPhase 3

Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)

NCT05569954 · Pneumococcal Disease

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 7, 2021Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment60

Start dateMay 2020

Last updatedOct 7, 2021

Condition

Pneumococcal Disease

Locations shown

The Catholic University of Seoul St.Mary's Hospital

Seoul

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 7, 2021Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions